Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 16.715. At the end of 2023 the company had a P/S ratio of 13.6.
Year | P/S ratio | Change |
---|---|---|
2023 | 13.6 | 12.21% |
2022 | 12.2 | 4.89% |
2021 | 11.6 | 40.15% |
2020 | 8.27 | 8.61% |
2019 | 7.61 | 19.98% |
2018 | 6.35 | -16.63% |
2017 | 7.61 | 33.98% |
2016 | 5.68 | -40.33% |
2015 | 9.52 | 31.16% |
2014 | 7.26 | 6.83% |
2013 | 6.79 | 1.79% |
2012 | 6.68 | 22.64% |
2011 | 5.44 | -13.47% |
2010 | 6.29 | 50.04% |
2009 | 4.19 | 17.18% |
2008 | 3.58 | -32.99% |
2007 | 5.34 | 33.24% |
2006 | 4.01 | 21.24% |
2005 | 3.31 | -9.26% |
2004 | 3.64 | 8.82% |
2003 | 3.35 | 16.88% |
2002 | 2.86 | -28.15% |
2001 | 3.99 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Pfizer PFE | 2.80 | -83.24% | ๐บ๐ธ USA |
Eli Lilly LLY | 20.4 | 22.02% | ๐บ๐ธ USA |
Sanofi SNY | 2.44 | -85.41% | ๐ซ๐ท France |
Bristol-Myers Squibb BMY | 1.96 | -88.25% | ๐บ๐ธ USA |